CellVax
Cellvax | Preclinical CRO | Expertise in Oncology and Osteoarthritis.
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
| % growth | 20 % | (26 %) | (83 %) | 413 % | 33 % | - | 80 % |
| EBITDA | <1m | <1m | (<1m) | <1m | - | - | - |
| % EBITDA margin | 39 % | 38 % | (588 %) | 40 % | - | - | - |
| Profit | <1m | <1m | (<1m) | <1m | - | - | - |
| % profit margin | 39 % | 64 % | (451 %) | 47 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | - | ||
€260k | Grant | ||
| Total Funding | AUD442k | ||
Related Content
Recent News about CellVax
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.